Mirabegron Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 25mg, 50mg
Reference Brands: Myrbetriq (USA), Betmiga (EU/UK), Mirago (India)
Category:
Urology
Mirabegron is a beta-3 adrenergic receptor agonist used for the treatment of overactive bladder (OAB), a condition characterized by symptoms such as urinary urgency, increased frequency, and urge incontinence. It works by relaxing the detrusor smooth muscle of the bladder, allowing it to store more urine and reduce the urge to urinate frequently.
Mirabegron Tablet is available in Tablet
and strengths such as 25mg, 50mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Mirabegron Tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Mirabegron Tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Mirabegron is a sympathomimetic agent indicated for the management of overactive bladder (OAB) with symptoms of urge urinary incontinence, urinary urgency, and increased urinary frequency. It was approved by the United States Food and Drug Administration (FDA) in June 2012 as a novel therapeutic option for patients who require an alternative to antimuscarinic therapy. Mirabegron acts as a selective beta-3 adrenergic receptor agonist, stimulating receptors in the detrusor muscle of the bladder. This action promotes relaxation of the bladder during the storage phase of the micturition cycle, thereby increasing bladder capacity and reducing involuntary contractions.
Mirabegron is generally administered as an extended-release oral tablet and is designed for once-daily dosing. It is particularly useful in patients who cannot tolerate anticholinergic adverse effects such as dry mouth or constipation. The medication is metabolized primarily in the liver and requires dose considerations in patients with severe renal or hepatic impairment. Common adverse effects may include hypertension, nasopharyngitis, urinary tract infection, and headache. Careful monitoring is recommended in patients with uncontrolled hypertension or those taking interacting medications.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing